The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
Abstract
In patients with advanced multiple myeloma (MM) there is an excess of production of interleukin-6 (IL-6) in vivo, and elevated serum levels are associated with plasmablastic proliferative activity and short survival. These data prompted us to perform a clinical trial with a murine anti-IL-6 monoclonal antibody (MoAb) to neutralize the excess of this putatively deleterious factor in these patients. Ten MM patients with extramedullary involvement frequently were treated with anti-IL-6 MoAb. The MoAb was administered intravenously to 9 patients; 1 patient with malignant pleural effusion received intrapleural therapy. Of the 3 patients who succumbed to progressive MM after less than 1 week of treatment (including the only 1 treated locally), 2 with evaluable data exhibited marked inhibition of plasmablastic proliferation. Among the 7 patients remaining more homogeneous receiving the anti-IL-6 MoAb for more than 1 week, 3 had objective antiproliferative effect marked by a significant reduction of the myeloma cell labelling index within the bone marrow. One of these 3 patients achieved a 30% regression of tumor mass. However, none of the patients studied achieved remission or improved outcome as judged by standard clinical criteria. Of major interest, objective antiproliferative effects were associated with complete inhibition of C-reactive protein (CRP) synthesis and low daily IL-6 production in vivo. On the other hand, the lack of effect in 4 patients was associated with a higher IL-6 production and inability of the MoAb to neutralize it. Anti-IL-6 was also associated with resolution of low-grade fever in all the patients and with worsening thrombocytopenia and mild neutropenia. The generation of human antibodies to Fc fragment of the murine anti-IL-6 MoAb observed in 1 patient was associated with dramatic progression. These data show that anti-IL-6 MoAb can suppress the proliferation of myeloma cells and underscore the biologic role of IL-6 for myeloma growth in vivo. Furthermore, suppression of CRP and worsening of neutropenia/thrombocytopenia both indicate that IL-6 is critically involved in acute-phase responses and granulopoiesis/thrombopoiesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Biological and clinical aspects of interleukin 6
Hirano, T., Akira, S., Taga, T., & Kishimoto, T. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90173-7 · Cited by 1,066
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
Klein, B., Zhang, X., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v73.2.517.517 · Cited by 763
Self-citationCastell, J. V., Gómez-lechón, M. J., David, M., Fabra, R., Trullenque, R., & Heinrich, P. C. (1990) · Hepatology · doi:10.1002/hep.1840120517 · Cited by 757
Bataille, R., Jourdan, M., Zhang, X. G., & Klein, B. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114392 · Cited by 479
Self-citationMurine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Self-citationIn vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets
Asano, S., Okano, A., Ozawa, K., Nakahata, T., Ishibashi, T., Koike, K., Kimura, H., Tanioka, Y., Shibuya, A., & Hirano, T. (1990) · Blood · doi:10.1182/blood.v75.8.1602.1602 · Cited by 279
Zhang, X., Gaillard, J., Robillard, N., Lu, Z., Gu, Z., Jourdan, M., Boiron, J., Bataille, R., & Klein, B. (1994) · Blood · doi:10.1182/blood.v83.12.3654.3654 · Cited by 276
Self-citationInterleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma
Zhang, X., Klein, B., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v74.1.11.11 · Cited by 266
Self-citation
Cited by
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Considering the properties of IL-6, an anti-IL-6 therapy against multiple myeloma was tried in the 1990s (69).”
BackgroundMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730
Metadata
- Authors
- Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1995-07-15
- Volume
- 86
- Issue
- 2
- Pages
- 685-691
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2289177026
- Cited by
- 269
- References
- 25
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. https://app.cochat.ai/papers/10.1182/blood.v86.2.685.bloodjournal862685
- The paper
- Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. https://doi.org/10.1182/blood.v86.2.685.bloodjournal862685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.